Clinical Trial Update: Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Dose Response [Phase 2]

View source ↗

Summary

Phase 2 dose-response evaluation of the T.R.U.E. TEST Panel 3.2 allergens in contact dermatitis has completed, with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Contact Dermatitis

Drugs mentioned

• T.R.U.E. TEST Panel 3.2 Allergens

Snippet

Sponsor: Allerderm | Conditions: Contact Dermatitis | Phase 2 | Status: COMPLETED | Results posted: 2018-04-09